Resveratrol for Alzheimer's Disease
Also known as: trans-Resveratrol
Resveratrol's sirtuin activation and anti-inflammatory properties target multiple Alzheimer's pathological pathways.
Mechanism of Action
Resveratrol activates SIRT1, promoting mitochondrial biogenesis (via PGC-1α), autophagic clearance of amyloid-beta, and reduction of NF-κB-driven neuroinflammation. It also inhibits GSK3β (reducing tau phosphorylation), scavenges ROS, and modulates microglial activation toward an anti-inflammatory phenotype.
General mechanism: Stilbenoid polyphenol. SIRT1 activator, NF-κB inhibitor, PGC-1α inducer, antioxidant. Multiple anti-aging and anti-cancer targets.
Current Evidence
Phase II trial in mild-moderate Alzheimer's showed resveratrol crossed the BBB and reduced CSF MMP-9 (neuroinflammation marker). Changes in Aβ40 levels suggested altered amyloid processing. Bioavailability remains a significant limitation. Enhanced formulations being studied.
Clinical Status: Phase II completed for Alzheimer's. Bioavailability challenges. No FDA-approved indication for AD.
Safety Profile
Very safe. GI effects at high doses. Rapid metabolism limits bioavailability. May interact with anticoagulants.
Key Research Questions
- Can micronized or liposomal resveratrol achieve therapeutically relevant brain concentrations?
- Does SIRT1 activation have disease-modifying potential in early Alzheimer's?